Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
EP3384915B1	CARRIMYCIN FOR THE TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS	Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.	1. Carrimycin for use in treating tubercle bacillus infections 2. A composition comprising carrimycin as an active ingredient and a pharmaceutically acceptable carrier for use in treating tubercle bacillus infections	Shenyang Fuyang Pharmaceutical Technology Co. Ltd., Shenyang, Liaoning 110013, CN, 101688131 | SHENYANG FUYANG PHARMACEUTICAL TECH CO LTD	2020-02-19	2015-12-31
EP3294387B1	ATTACHMENT FOR OR ON A DEVICE FOR INJECTING A FLUID INTO OR UNDER THE SKIN	An attachment (1, 1a) for or on a device (100) for injecting a fluid into or under the skin (200), suitable, for example, for the injection of botulinum toxin into face muscles of a human patient, has: a proximal part (2, 2a) which can be coupled to the device (100) or is connected to the same, and which has a cannula (3). A distal part (4, 4a) surrounds the cannula (3) at least in sections and is rotatably movable with respect to the proximal part (2, 2a) and vice versa, so that one dimension (d3) of the projection of the cannula out of the distal part (2, 2a) is changeable. A discrete number of stopping positions is provided with respect to the rotatable movement, to which a different dimension of the projection of the cannula (3) out of the distal part (2, 2a) corresponds.	1. Attachment (1, 1a) for or on an apparatus (100) for injecting a liquid into or under the skin (200), wherein the attachment (1, 1a) comprises: a proximal part (2, 2a) which can be coupled to or connected to the apparatus (100) and which carries a cannula (3), a distal part (4, 4a) which surrounds the cannula (3) at least sectionwise, and wherein the proximal part (2, 2a) and the distal part (4, 4a) are rotationally movable relative to each other in such a way that an extent (d 3) of the protrusion of the cannula (3) from the distal part (4, 4a) is variable, wherein a discrete number of holding positions with respect to the rotational motion is provided, to which correspond a different extent of the protrusion of the cannula (3) from the distal part (4, 4a), characterized in that the attachment features a locking mechanism(10) with a gear rim of axially extending teeth (13) with axially extending grooves (14) therebetween and with an elastic locking member (15) engaging in a locking position in one of the grooves (14) to provide the discrete number of holding positions through a plurality of locking positions.	Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., 78052 Villingen-Schwenningen, DE, 100135205 | HAHN SCHICKARD GES FUER ANGEWANDTE FORSCHUNG E V	2020-02-05	2015-05-13
EP3226854B1	AMINOACID-BASED COMPOSITION FOR FIBROELASTIN RECOVERY IN DERMAL CONNECTIVE TISSUES	The present invention relates to compositions containing, as active ingredient, a mixture of amino acids able to stimulate the biosynthesis of elastin and collagen.	1. Compositions containing, as active ingredient, a mixture of amino acids consisting of glycine, L-proline, L-alanine, L-valine, L-leucine and L-lysine hydrochloride in the following weight ratios: - Glycine 1; - L-proline: 0.7-0.8; - L-alanine: 0.47-0.76; - L-valine: 0.35-0.56; - L-leucine: 0.13-0.27; - L-lysine hydrochloride: 0.10-0.12.	Professional Dietetics International S.r.l. in forma abbreviata P.D. INT. S.R.L., 20129 Milano, IT, 101725472 | PROFESSIONAL DIETETICS INT S R L IN FORMA ABBREVIATA P D INT S R L	2020-02-26	2014-12-04
EP3217958B1	SUSTAINED RELEASE ENCAPSULATED NANOPARTICLES	The present invention provides a microparticle comprising at least one biocompatible polymer, the microparticle encapsulating at least one nanoparticle, the nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise at least one carbohydrate and/or glutathione. The	1. A microparticle comprising at least one biocompatible polymer, the microparticle encapsulating at least one nanoparticle, the nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise at least one carbohydrate and/or glutathione, wherein	Midatech Ltd, Milton Park, Milton, Abingdon, Oxfordshire OX14 4RD, GB, 101534176 | Midatech Pharma (Wales) Limited, Cardiff, South Glamorgan CF24 0AA, GB, 101679427 | MIDATECH LTD | MIDATECH PHARMA WALES LTD	2020-02-26	2014-11-11

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		nanoparticle may additionally comprise a biologically active agent or detectable label covalently linked or non-covalently bound to said corona and/or said core. Also disclosed are pharmaceutical compositions comprising the microparticles, processes for their production and uses of the microparticles in methods of therapy.	the microparticle has a diameter along its longest dimension that is within the range 10 µm to 75 µm.			
EP3206665B1	ANHYDROUS LIQUID MELATONIN COMPOSITION	The present invention relates to a concentrated melatonin solution, wherein melatonin is present in a quantity of 10.0 % or higher in a substantially water-free carrier mixture of ethanol and a polyethoxylated derivative. The concentrated solution, free of preserving agents, is suitable to prepare injectable sterile compositions for parenteral administration, or formulations for topical or oral administration. The invention also encompasses a method for the preparation of the concentrated solution, as well as the possible benefits of the intravenous infusion of high levels of melatonin as adjuvant therapy in Ebola or Dengue hemorrhagic fever (DHF) or as an anti-oxidant/anti-aging treatment.	1. A substantially water-free parenteral bulk solution consisting of an anhydrous liquid preparation of melatonin containing at least: a) melatonin (MLT) quantitatively at the concentration of or higher than 10.0 % weight/volume of the bulk solution; b) a polyethoxylated derivative (PED) selected among macrogolglycerol hydroxystearate, preferably polyoxyl 40 hydrogenated castor oil, or macrogolglycerol ricinoleate, preferably polyoxyl 35 castor oil, or macrogol 15 hydroxystearate, also polyoxyl 15 hydroxystearate, or a mixture thereof; whereas the mass ratio MLT/PED is 1 : 1 (weight/weight); and c) ethanol 10 volumes.	Worphmed Srl, 20146 Milan, IT, 101764778 | WORPHMED SRL	2020-02-26	2014-10-13
EP3169307B1	AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN	The present invention relates to an aqueous ibuprofen and paracetamol composition of pH 6.3-7.3and to its use. The present invention relates to a method for preparing a combination product of ibuprofen and paracetamol. It also relates to the compositions for use as a medicament, especially for the treatment of pain and/or inflammation;especially for administration of the composition by intravenous injection.	1. A process for manufacturing an aqueous composition with a pH of 6.3-7.3 comprising ibuprofen and paracetamol in combination, comprising the steps of: a) providing an aqueous solvent of pH 6.0-8.0, preferably 6.2-7.5, more preferably 6.3-7.3, b) dissolving in said aqueous solvent ibuprofen and paracetamol, c) ensuring that the final composition comprising ibuprofen and paracetamol has a pH of 6.3-7.3. 7. An aqueous composition, comprising ibuprofen and paracetamol, characterized in that , the pH of said composition is 6.3 to 7.3.	Hyloris Pharmaceuticals sa, 4000 Liège, BE, 101845967 | HYLORIS PHARMACEUTICALS SA	2020-02-19	2014-07-18
EP3169351B1	USE OF HYALURONIDASE FOR TREATMENT OF MUSCLE STIFFNESS	Provided are methods and kits for reducing the severity of muscle stiffness. The method comprises delivering to one or more specific locations in the deep fascia of an affected muscle a composition comprising a therapeutically effective amount of hyaluronidase.	1. A composition comprising hyaluronidase for use in a method for providing relief from stiffness of a first muscle in an individual comprising the steps of delivering said composition in a region of deep fascia surrounding the first muscle or in a region of deep fascia surrounding a second muscle that affects the function of the first muscle at or near one or more centers of coordination or center of fusion associated with the first muscle, second muscle or a combination thereof, wherein a center of coordination or center of fusion is characterized by slidable layers in the deep fascia, and wherein delivering the composition results in reduction of stiffness of the first muscle. 7. A kit for use in reducing stiffness of muscles, the kit comprising: a) one or more combined or individual doses of hyaluronidase; b) optionally, reconstitution medium to reconstitute the one or more doses of hyaluronidase in a); and c) one or more charts depicting	New York University, New York City, NY 10012, US, 101170182 | UNIV NEW YORK	2020-02-26	2014-07-16

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			centers of coordination and/or centers of fusion, said centers of coordination or centers of fusion providing sites for administration of the hyaluronidase.			
EP3062618B1	CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF	Described herein is certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.	7-(3-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane in crystalline Form A or crystalline Form B, wherein Form A is a form of 7-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane having an X-ray powder diffraction (XRPD) pattern with peaks at 6.11±0.3, 9.63±0.3, 16.41±0.3, 18.60±0.3, 20.36±0.3 and 23.01±0.3 degrees two theta, or 1.445±0.03, 0.917±0.03, 0.540±0.03, 0.477±0.03, 0.436±0.03 and 0.386±0.03 nm (14.45±0.3, 9.17±0.3, 5.40±0.3, 4.77±0.3, 4.36±0.3 and 3.86±0.3 Å) in d-spacing, wherein Form B is a form of 7-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane having an X-Ray Powder Diffraction (XRPD) pattern with peaks at 7.70±0.3, 13.53±0.3, 17.27±0.3, 18.44±0.3, 19.73±0.3, 23.10±0.3 and 26.07±0.3 degrees two theta or 1.147±0.03, 0.654±0.03, 0.513±0.03, 0.481±0.03, 0.450±0.03, 0.385±0.03 and 0.341±0.03 nm (11.47±0.3, 6.54±0.3, 5.13±0.3, 4.81±0.3, 4.50±0.3, 3.85±0.3 and 3.41±0.3 Å) in d-spacing, and wherein the XRPD pattern is obtained using Cu/Kα radiation at a wavelength of 0.154059 nm (1.54059 Å).	Kala Pharmaceuticals Inc., Watertown, MA 02472, US, 101809891 | KALA PHARMACEUTICALS INC	2020-02-05	2013-11-01
EP3060245B1	INTRA-AMNIOTIC ADMINISTRATION OF PROTEINS FOR THE TREATMENT OF ECTODERMAL DYSPLASIAS	The disclosure relates to methods for the intra-amniotic administration of ectodysplasin A (EDA) agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, X-linked hypohidrotic ectodermal dysplasia (XLHED).	1. A pharmaceutical composition comprising EDI200 for use in altering one or more phenotypic presentations of ectodermal dysplasia in a mammalian organism diagnosed with or suspected of having ectodermal dysplasia, wherein administration is via an intra-amniotic route and intra-amniotic administration is effected via direct injection into the amniotic sac or via catheter infusion to the amniotic sac. 8. A pharmaceutical composition comprising EDI200 for use in treating hypohidrotic ectodermal dysplasia in a mammalian organism diagnosed with or suspected of having hypohidrotic ectodermal dysplasia, wherein administration is via an intra-amniotic route and intra-amniotic administration is effected via direct injection into the amniotic sac or via catheter infusion to the amniotic sac.	EspoirXLHED Sàrl, 1202 Genève, CH, 101815816 | Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, DE, 100125789 | ESPOIRXLHED SARL | UNIV FRIEDRICH ALEXANDER ER	2020-02-26	2013-10-22
EP3052628B1	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE	The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.	1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of ALAS1, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to an ALAS1 RNA transcript (e.g., SEQ ID NO:1), which antisense strand comprises	Alnylam Pharmaceuticals Inc., Cambridge, MA 02142, US, 101214756 | Icahn School of Medicine at Mount Sinai, New York, NY 10029, US, 101412820 | ALNYLAM	2020-02-26	2013-10-04

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			usAfsAfGfaUfgAfgAfcAfcUfcUfuUfcUfgsgsu (SEQ ID NO: 4161), wherein c, a, g, u = 2'-OMe ribonucleosides; Af, Cf, Gf, Uf = 2'F ribonucleosides; s = phosphorothioate, or a sequence differing by no more than 1, 2, or 3 nucleotides thereof.	PHARMACEUTICALS INC | ICAHN SCHOOL MED MOUNT SINAI		
EP2934593B1	CABAZITAXEL COMPOSITION	The present invention is directed to a composition comprising (a) cabazitaxel and (b) sulfobutyl ether beta cyclodextrin. Such composition exhibits unexpectedly desirable stability in aqueous media, permitting therapeutic dosages of the drug to be administered without the use of either ethanol or surfactants.	1. A composition comprising: (a) cabazitaxel, and (b) a sulfobutylether beta-cyclodextrin, wherein such composition does not contain any ethanol.	Softkemo Pharma Corp., Montreal, QC H3B 4W5, CA, 101838977 | SOFTKEMO PHARMA CORP	2020-02-05	2012-12-24
EP2922590B1	DRUG DELIVERY DEVICE	A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.	1. A drug delivery device (50, 60) comprising: a housing (200), the housing (200) having an opening (208) through which the blunt cannula or the rigid needle (100) is disposed in an operative state, a blunt cannula or a rigid needle (100) having a cylindrical wall (102) that defines an axial passage (104) between a first end (106) and a second end (108) of the blunt cannula or the rigid needle (100), the wall (102) having at least a first tapered region (110) at the first end (106) to define an opening (112) in fluid communication with the axial passage (104) and adapted at the first end (106) to resist interruption of fluid flow through the axial passage (104) and out of the first end (106) of the blunt cannula or the rigid needle (100), wherein the blunt cannula or rigid needle (100) is configured to be deployed through the opening (208) in the operative state; and a reservoir (52) connected to the second end (108) of the blunt cannula or the rigid needle (100); characterized by at least a pair of side ports (130) formed in the wall (102) of the blunt cannula or rigid needle (100) at the first end (106), which pair of side ports (130) are aligned with each other across the axial passage (104).	Amgen Inc., Thousand Oaks, California 91320-1799, US, 101250726 | AMGEN INC	2020-02-05	2012-11-21
EP2906580B1	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS	Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.	1. An in vitro method of reducing TDP-43 toxicity in a human neuronal cell or human glial cell suffering from or susceptible to such toxicity, comprising: providing to the cell a therapeutically effective amount of a UPF1 polypeptide, thereby reducing the TDP-43 toxicity in the cell. 4. A UPF1 polypeptide for use in the treatment of amyotrophic lateral sclerosis (ALS) in a human subject, wherein the UPF1 polypeptide is to be administered to a subject suffering from or susceptible to ALS, and wherein (i) the ALS is associated with TDP-43 toxicity; or (ii) the subject does not have a mutation in a SOD1 gene. 8. A pharmaceutical composition comprising a UPF1 polypeptide or a nucleic acid encoding a UPF1	Brandeis University, Waltham, MA 02454, US, 101036870 | UNIV BRANDEIS	2020-02-19	2012-10-11

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			polypeptide, and a pharmaceutically acceptable excipient for use in treating ALS, wherein (i) the ALS is associated with TDP-43 toxicity; or (ii) the subject having ALS does not have a mutation in a SOD1 gene. 12. A nucleic acid encoding UPF1 polypeptide for use in treating ALS in a human subject suffering from or susceptible to ALS, wherein (i) the ALS is associated with TDP-43 toxicity; or (ii) the subject does not have a mutation in a SOD1 gene.			
EP2707030B1	CANCER TREATMENTS		1. A composition comprising albumin-containing nanoparticle/antibody complexes, wherein the complex comprises: (a) a nanoparticle formulation that combines paclitaxel with human albumin; and (b) an antibody, wherein the antibody is an anti-VEGF polypeptide antibody, trastuzumab or rituximab.	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, Rochester, MN 55905, US, 100174229 | MAYO FOUND MEDICAL EDUCATION & RES	2020-02-19	2011-05-09
EP3254703B1	ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF	The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.	1. A recombinant adeno-associated virus (rAAV) virion or pharmaceutical composition comprising said virion, for use in a method of treating an ocular disease in an individual in need thereof, wherein the composition comprises a pharmaceutically acceptable excipient, and wherein the recombinant adeno-associated virus (rAAV) virion comprises: a) a variant AAV capsid protein, wherein the variant AAV capsid protein comprises an insertion of a peptide in the capsid protein GH loop relative to a corresponding parental AAV capsid protein, wherein the insertion comprises an amino acid sequence selected from LALGETTRPA (SEQ ID NO:45); LANETITRPA (SEQ ID NO:46), LAKAGQANNA (SEQ ID NO:47), LAKDPKTTNA (SEQ ID NO:48), KDTDTTR (SEQ ID NO:57), RAGGSVG (SEQ ID NO:58), AVDTTKF (SEQ ID NO:59), STGKVPN (SEQ ID NO:60), LAKDTDTTRA (SEQ ID NO:61), LARAGGSVGA (SEQ ID NO:62), LAAVDTTKFA (SEQ ID NO:63), and LASTGKVPNA (SEQ ID NO:64); and b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product; wherein the variant capsid protein infects a retinal cell. 7. A recombinant adeno-associated virus (rAAV) virion comprising: a) a variant AAV capsid protein, wherein the variant AAV capsid protein comprises an insertion of a peptide in the capsid protein GH loop relative to a corresponding parental AAV capsid protein, wherein the insertion comprises an amino acid sequence selected from LALGETTRPA (SEQ ID NO:45); LANETITRPA (SEQ ID NO:46), LAKAGQANNA (SEQ ID NO:47), LAKDPKTTNA (SEQ ID NO:48), LAKDTDTTRA (SEQ ID NO:61), LARAGGSVGA (SEQ ID NO:62), LAAVDTTKFA (SEQ ID NO:63), and LASTGKVPNA (SEQ ID NO:64), and wherein the variant capsid protein confers infectivity of a retinal cell; and b) a heterologous nucleic	The Regents of the University of California, Oakland, CA 94607, US, 100236880 | UNIV CALIFORNIA	2020-02-19	2011-04-22

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			acid comprising a nucleotide sequence encoding a gene product.			
EP3275507B1	VACCINE DELIVERY METHOD	The present invention relates to a vaccine composition comprising:(i) a peptide hydrogel that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures; and (ii) one or more antigens; wherein the peptide hydrogel comprises a self-assembling peptide selected from the group consisting of RAD16-I ((RADA)(4); (SEQ ID NO:2)), RAD16-II ((RARADADA)(2); (SEQ ID NO:3)), KFE-8 ((FKFE)(2); (SEQ ID NO:4)), and KLD-12 ((KLDL)(3)); (SEQ ID NO:5)).	1. A vaccine composition comprising: (i) a peptide hydrogel that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures; and (ii) one or more antigens; wherein the peptide hydrogel comprises the self-assembling peptide RADARADARADARADA (SEQ ID NO:2).	University Of Georgia Research Foundation Inc., Athens, GA 30602, US, 101352485 | UNIV OF GEORGIA RESEARCH FOUNDATION INC	2020-02-26	2011-04-18
EP2664340B1	A direct drug delivery system based on thermally responsive biopolymers	A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described.	1. A pharmaceutically acceptable composition for delivering a drug depot by injection to a selected region in a subject, wherein said composition comprises a therapeutic compound coupled to a polymer as a fusion protein, wherein said polymer undergoes an inverse temperature phase transition and has a transition temperature less than the body temperature of the subject such that a sustained release of said therapeutic compound is provided, and further wherein said polymer is an Elastin-like polypeptide (ELP) comprising [(VPGVG)5(VPGGG)3(VPGAG)2]9 (SEQ. ID. NO:20). 8. A pharmaceutically acceptable composition comprising a therapeutic compound coupled to a polymer as a fusion protein, wherein said polymer undergoes an inverse temperature phase transition and has a transition temperature less than the body temperature of a subject to be treated such that a sustained release of said therapeutic compound is provided upon injection, and further wherein said polymer is an Elastin-like polypeptide (ELP) comprising [(VPGVG)5(VPGGG)3(VPGAG)2]9 (SEQ. ID. NO:20), for use as a medicament.	DUKE UNIVERSITY, Durham NC 27707, US, 100742897 | UNIV DUKE	2020-02-12	2005-06-24
EP1879553B1	OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES	Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic	1. An ophthalmically therapeutic material, comprising: a therapeutic component comprising a therapeutically effective amount of an alpha 2 adrenergic receptor agonist having a structure effective in providing elimination of the agonist from the anterior chamber of an eye to which the agonist is administered, wherein the alpha 2 adrenergic receptor agonist is selected from: 11. A method of producing an ophthalmically therapeutic material, comprising: selecting an alpha 2 adrenergic receptor agonist, ; and combining the selected alpha 2 adrenergic receptor agonist with a liquid carrier component or a polymeric component to form a material suitable for administration to an eye, wherein	ALLERGAN INC., Irvine, CA 92612, US, 100074706 | ALLERGAN INC	2020-02-12	2005-05-10

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.	the alpha 2 adrenergic receptor agonist is selected from:			